Medical Field: Gynecology
Award: Finalist
Country: Slovenia
Year: 2023
Research Work: Decreased Gene Expression of Antiangiogenic Factors in Endometrial Cancer: qPCR Analysis and Machine Learning Modelling
Published in: Cancers

The International Medis Awards stand as a unique example for acknowledging and appreciating the significance of clinical research work in general. In a society where such contributions may often be overlooked, the Awards recognize the importance of advancing medical knowledge through research and the positive impact it can have on healthcare outcomes.


Luka Roškar, MD, PhD, is a specialist in gynecology and obstetrics and head of the Gynecology and Obstetrics Department at the General Hospital Murska Sobota, Slovenia. He obtained a medical degree in 2012 from the University of Ljubljana and completed specialization in gynecology and obstetrics with honors in 2018. In 2023, he also completed his doctoral degree.

His interest in medicine was sparked during high school years. Several factors contributed to this growing fascination, such as the inherent desire to help others and make a positive difference in their lives, the dynamic nature of the medical field and his intense interest in the sciences.

Curiosity and a genuine passion for exploring new ideas, theories, and therapeutic approaches in his clinical field are powerful drivers for his research work. For his work he was awarded the International Medis Award in 2021 and the Diakomanolis Award by the European Federation for Colposcopy (EFC) in 2022.

His research provides insights into the molecular characteristics of endometrial cancer, which can help better understand the disease and its progression. The study identifies specific genes involved in angiogenesis and their expression patterns in endometrial cancer tissue. His research of angiogenic factors is focused on the identification of the potential biomarkers for early diagnosis, prognosis, and treatment response in endometrial cancer patients.

By understanding the gene expression profiles in endometrial cancer tissue, it may be possible to tailor treatment approaches based on the individual molecular characteristics of the tumors, leading to more personalized and effective treatments for patients.